Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry SummitBusiness Wire • 09/23/24
Compass Pathways announces second quarter 2024 financial results and business highlightsGlobeNewsWire • 08/01/24
Compass Pathways to announce second quarter financial results on August 1, 2024GlobeNewsWire • 07/24/24
Compass Pathways: Buy It For Its Promising Psychedelic Mental Health TherapiesSeeking Alpha • 07/08/24
Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceGlobeNewsWire • 06/24/24
Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.The Motley Fool • 06/10/24
Compass Pathways Announces First Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 05/08/24
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorderGlobeNewsWire • 05/08/24
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatmentGlobeNewsWire • 05/02/24
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depressionGlobeNewsWire • 04/29/24
Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/01/24
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of DirectorsGlobeNewsWire • 03/28/24